Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients

September 12, 2016 updated by: Jinsong Wang

Comparison of Microbiota and Quality of Life for a Low FODMAPs Versus Standard Dietary Advice in Patients With Irritable Bowel Syndrome

IBS is a global disease, patients often because of long-term symptoms of recurrent, not timely diagnosis and treatment effect is not ideal and frequent treatment, seriously affect the quality of life, and cause the corresponding economic and social burden.At present，a number of studies suggest that fermentable oligosaccharides, disaccharides and monosaccharides and polyols (FODMAPs) can induce IBS symptoms.Data from large randomized controlled trials are limited, leaving clinicians with the challenge of providing patients with reliable guidance based on minimal evidence.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

IBS is a global disease, patients often because of long-term symptoms of recurrent, not timely diagnosis and treatment effect is not ideal and frequent treatment, seriously affect the quality of life, and cause the corresponding economic and social burden.At present，a number of studies suggest that fermentable oligosaccharides, disaccharides and monosaccharides and polyols (FODMAPs) can induce IBS symptoms.Data from large randomized controlled trials are limited, leaving clinicians with the challenge of providing patients with reliable guidance based on minimal evidence.

This study will compare the effect of low FODMAPs diet and usual diet instruction on Intestinal flora, intestinal short chain fatty acids and quality of life by two groups.The results will answer the effect and long-term safety of Low FODMAPs diet.

Study Type

Interventional

Enrollment (Anticipated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Jiangsu
      • Yangzhou, Jiangsu, China, 225001
        • Recruiting
        • YangzhouUniversity
        • Contact:
        • Contact:
        • Principal Investigator:
          • Jinsong Wang, Ph.D.,M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnostic criteria for Rome Ⅲ
  • IBS patients with diarrhea type
  • By endoscopy, X-ray, B ultrasound and laboratory examination to exclude organic disease
  • Patients be able to communicate well with the researchers and be willing to participate in the study

Exclusion Criteria:

  • Stomach, small intestine, colon surgery history
  • irritable bowel disease (IBD) active period, celiac disease
  • Alcoholics or drug abuse
  • Pregnant or lactating women
  • Recent drug users who use defecation
  • Have a special diet

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low FODMAPs Diet
  1. Instructed to low FODMAPs diet when patients signed the informed consent.
  2. Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
Behavioral: Low FODMAPs Diet
Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
Behavioral: Diet instruction
Answer the doubt and help the patient get the diet knowlege about the IBS.
Placebo Comparator: Diet Instruction
1.Answer doubts and correct unhealthy dietary behaviors,such as excessive diet, eating raw, spirits and other excitant food.
Behavioral: Diet instruction
Answer the doubt and help the patient get the diet knowlege about the IBS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microbiota / Short chain fatty acids
Time Frame: Change from baseline Microbiota / Short chain fatty acids at 4 weeks
The fecal samples of IBS patients were analyzed.
Change from baseline Microbiota / Short chain fatty acids at 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Irritable bowel syndrome severity scoring system scale
Time Frame: Baseline,1,and 3 month post randomization
Irritable bowel syndrome severity scoring system scale is an integral system for monitoring the severity of IBS in patients with disease severity.The scale is mainly from the degree of abdominal pain, abdominal pain frequency, abdominal distension, defecation satisfaction and the impact of life, according to the 10cm visual scoring method
Baseline,1,and 3 month post randomization
The Short Form 36 (SF-36) scale
Time Frame: Baseline,1,and 3 month post randomization
SF-36 is a general scale, at present, the most commonly used evaluation of IBS. It includes 36 items, a total of 8 dimensions
Baseline,1,and 3 month post randomization
Irritable bowel syndrome quality of life (IBS-QOL) scale
Time Frame: Baseline,1,and 3 month post randomization
Irritable bowel syndrome quality of life (IBS-QOL) scale is a more extensive application of the specific scale of IBS.
Baseline,1,and 3 month post randomization
Satisfaction questionnaire
Time Frame: 1,and 3 month post randomization
To understand the patient's satisfaction with symptom control and diet guidance. The questionnaire included 3 items
1,and 3 month post randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jinsong Wang

Investigators

  • Study Chair: Hongcan Shi, Ph.D.,M.D., Medical College

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2016

Primary Completion (Anticipated)

December 1, 2016

Study Completion (Anticipated)

March 1, 2017

Study Registration Dates

First Submitted

August 15, 2016

First Submitted That Met QC Criteria

September 12, 2016

First Posted (Estimate)

September 16, 2016

Study Record Updates

Last Update Posted (Estimate)

September 16, 2016

Last Update Submitted That Met QC Criteria

September 12, 2016

Last Verified

September 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20160805

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Food Habits

Clinical Trials on Low FODMAPs Diet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe